Six-year results from the phase 3 randomized study relevance show similar outcomes for previously untreated follicular lymphoma patients receiving lenalidomide plus rituximab (R (2)) versus rituximab-chemotherapy followed by rituximab maintenance Meeting Abstract

  

Authors:	Morschhauser, F.; Nastoupil, L.; Feugier, P.; De Colella, J. M. S.; Tilly, H.; Palomba, M. L.; Bachy, E.; Fruchart, C.; Libby, E.; Casasnovas, R. O.; Flinn, I. W.; Haioun, C.; Maisonneuve, H.; Ysebaert, L.; Bartlett, N. L.; Bouabdallah, K.; Brice, P.; Ribrag, V.; Le Gouill, S.; Daguindau, N.; Delwail, V.; Pica, G. M.; Garcia-Sancho, A. M.; Lopez-Guillermo, A.; Larouche, J. F.; Ando, K.; Maria, G. D.; André, M.; Wu, K. L.; Sehn, L. H.; Izutsu, K.; Cartron, G.; Gkasiamis, A.; Crowe, R.; Xerri, L.; Fowler, N. H.; Salles, G.
Abstract Title:	Six-year results from the phase 3 randomized study relevance show similar outcomes for previously untreated follicular lymphoma patients receiving lenalidomide plus rituximab (R (2)) versus rituximab-chemotherapy followed by rituximab maintenance
Meeting Title:	63rd Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	138
Issue:	Suppl. 1
Meeting Dates:	2021 Dec 11-14
Meeting Location:	Atlanta, GA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2021-11-23
Language:	English
ACCESSION:	WOS:000736413901148
DOI:	10.1182/blood-2021-148218
PROVIDER:	wos
Notes:	Meeting Abstract: 2417 -- Hybrid meeting, also took place online -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/198888